Skip to Content
Merck
All Photos(3)

Documents

C0737

Sigma-Aldrich

Cilostazol

≥98% (HPLC), powder

Synonym(s):

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C20H27N5O2
CAS Number:
73963-72-1
Molecular Weight:
369.46
MDL number:
MFCD00866780
UNSPSC Code:
41106305
PubChem Substance ID:
24278291
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

off-white

solubility

DMSO: 10 mg/mL, clear

originator

Otsuka Pharma

SMILES string

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChI key

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Gene Information

human ... PDE3A(5139) , PDE3B(5140)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.

Application

Cilostazol has been used:
  • to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
  • in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
  • to induce adenosine triphosphate (ATP) release in white adipocytes

Biochem/physiol Actions

Phosphodiesterase III (PDE3) inhibitor

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361d

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration
Tozzi M, et al.
bioRxiv, 380469-380469 (2018)
Kuang-Yi Tseng et al.
Medicina (Kaunas, Lithuania), 59(3) (2023-03-30)
Background and Objective: Our previous study demonstrated that consistent treatment of oral cilostazol was effective in reducing levels of painful peripheral neuropathy in streptozotocin-induced type I diabetic rats. As diabetic neuropathy is characterized by hyperglycemia-induced nerve damage in the periphery
Sayuri N Friedland et al.
The American journal of cardiology, 109(10), 1397-1404 (2012-03-03)
Cilostazol is a generic drug with antiplatelet and antiproliferative effects. It is unclear whether adding cilostazol to standard dual antiplatelet therapy (aspirin and clopidogrel) after percutaneous coronary intervention reduces restenosis and improves the outcomes. We, therefore, conducted a systematic review
James J Dinicolantonio et al.
The American journal of cardiology, 112(8), 1230-1234 (2013-07-06)
Aspirin is the most widely prescribed antiplatelet agent for the secondary prevention of stroke. Cilostazol, an antiplatelet and vasodilating agent, has shown promise for the secondary prevention of stroke. A systematic review and meta-analysis of randomized controlled trials using Ovid
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
Money SR, et al.
Journal of Vascular Surgery, 27(2), 267-275 (1998)
View All Related Papers

Articles

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service